Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
The Key Laboratory of Laboratory Medical Diagnostics in the Ministry of Education and Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400010, China.
Cell Commun Signal. 2019 Jan 25;17(1):8. doi: 10.1186/s12964-019-0321-y.
Ghrelin modulates many physiological processes. However, the effects of intestinal ghrelin on hepatic glucose production (HGP) are still unclear. The current study was to explore the roles of intestinal ghrelin on glucose homeostasis and insulin signaling in the liver.
The system of intraduodenal infusion and intracerebral microinfusion into the nucleus of the solitary tract (NTS) in the normal chow-diet rats and pancreatic-euglycemic clamp procedure (PEC) combined with [3-H] glucose as a tracer were used to analyze the effect of intestinal ghrelin. Intraduodenal co-infusion of ghrelin, tetracaine and Activated Protein Kinase (AMPK) activator (AICAR), or pharmacologic and molecular inhibitor of N-methyl-D-aspartate receptors within the dorsal vagal complex, or hepatic vagotomy in rats were used to explore the possible mechanism of the effect of intestinal ghrelin on HGP.
Our results demonstrated that gut infusion of ghrelin inhibited duodenal AMP-dependent protein kinase (AMPK) signal pathways, increased HGP and expression of gluconeogenic enzymes, and decreased insulin signaling in the liver of the rat. Intraduodenal co-infusion of ghrelin receptor antagonist [D-Lys]-GHRP-6 and AMPK agonist with ghrelin diminished gut ghrelin-induced increase in HGP and decrease in glucose infusion rate (GIR) and hepatic insulin signaling. The effects of gut ghrelin were also negated by co-infusion with tetracaine, or MK801, an N-methyl-D-aspartate (NMDA) receptor inhibitor, and adenovirus expressing the shRNA of NR1 subunit of NMDA receptors (Ad-shNR1) within the dorsal vagal complex, and hepatic vagotomy in rats. When ghrelin and lipids were co-infused into the duodenum, the roles of gut lipids in increasing the rate of glucose infusion (GIR) and lowering HGP were reversed.
The current study provided evidence that intestinal ghrelin has an effect on HGP and identified a neural glucoregulatory function of gut ghrelin signaling.
Ghrelin 调节许多生理过程。然而,肠 ghrelin 对肝葡萄糖生成 (HGP) 的影响尚不清楚。本研究旨在探讨肠 ghrelin 在葡萄糖稳态和肝脏胰岛素信号中的作用。
使用十二指肠内输注和孤束核(NTS)脑内微输注系统,以及正常饮食大鼠的胰腺葡萄糖钳夹(PEC)联合[3-H]葡萄糖示踪剂,分析肠 ghrelin 的作用。在大鼠中,十二指肠共输注 ghrelin、四卡因和蛋白激酶(AMPK)激活剂(AICAR),或在背侧迷走神经复合体中使用 N-甲基-D-天冬氨酸受体的药理学和分子抑制剂,或肝迷走神经切断术,以探讨肠 ghrelin 对 HGP 的作用的可能机制。
我们的结果表明,ghrelin 肠内输注抑制十二指肠 AMP 依赖性蛋白激酶(AMPK)信号通路,增加 HGP 和糖异生酶的表达,并降低肝脏的胰岛素信号。ghrelin 受体拮抗剂[D-Lys]-GHRP-6 和 ghrelin 与 AMPK 激动剂共输注可减弱 ghrelin 诱导的 HGP 增加和葡萄糖输注率(GIR)降低以及肝脏胰岛素信号。四卡因共输注或背侧迷走神经复合体中的 MK801(N-甲基-D-天冬氨酸(NMDA)受体抑制剂)和表达 NMDA 受体 NR1 亚单位的 shRNA 腺病毒(Ad-shNR1)以及大鼠肝迷走神经切断术也否定了 ghrelin 的作用。当 ghrelin 和脂质共输注到十二指肠时,肠脂质增加葡萄糖输注率(GIR)和降低 HGP 的作用被逆转。
本研究提供了证据表明,肠 ghrelin 对 HGP 有影响,并确定了肠 ghrelin 信号的神经糖调节功能。